The U.S. Food and Drug Administration has approved Insmed's oral drug for a type of lung disease, the company said on Tuesday ...

A first-in-class reversible dipeptidyl peptidase-1 (DPP-1) inhibitor, brensocatib addresses the underlying inflammatory ...

The U.S. Food and Drug Administration has approved Insmed's oral drug for a type of lung disease, the company said on Tuesday ...

Brinsupri, which Insmed acquired from AstraZeneca nearly a decade ago, is the first treatment for bronchiectasis that’s not ...

Abatacept is linked to lower mortality and fewer hospitalizations than rituximab in patients with rheumatoid ...

The U.S. Food and Drug Administration (FDA) on Tuesday approved Insmed Incorporated’s (NASDAQ:INSM) Brinsupri (brensocatib 10 ...

The spinout, known as Celea Therapeutics, will advance what’s designed to be an improved version of the drug pirfenidone for ...

Researchers have found a promising treatment breakthrough for chronic obstructive pulmonary disease (COPD) that avoids many ...

Pune: Infantry soldier Tariq Aziz (30) is set to return to active duty after undergoing a bilateral lung transplant — the ...

Insmed has received FDA clearance for the first treatment for a chronic lung disease, opening the biotech up to what could be ...

Brinsupri is the first approved therapy to address the underlying inflammatory process of non-cystic fibrosis bronchiectasis ...

Australian researchers who discovered “the old fashioned way” that an existing drug could be repurposed to better treat a ...